BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Liver cancer (HCC) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hepatocellular carcinoma: 218 (150 sponsors; 21 newly posted in the last 180 days, 10 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 7.8, rank 82 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 49, Phase 2 86, Phase 3 36, Phase 4 1, N/A 43.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 17 | NA 5, P2 5, P3 6, P1 1 | 2 | 1 |
| Hoffmann-La Roche | 4 | P3 3, NA 1 | 0 | 1 |
| Akeso | 6 | P2 4, P3 2 | 0 | 2 |
| Exelixis EXEL | 4 | P3 2, P1 2 | 1 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 4 | P3 2, P1 1, P2 1 | 2 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 | P3 2 | 0 | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 | P3 2 | 0 | 0 |
| AbbVie ABBV | 5 | P3 1, P1 3, P2 1 | 0 | 1 |
| Shanghai Henlius Biotech | 4 | P2 2, P1 1, P3 1 | 0 | 2 |
| BeOne Medicines ONC | 3 | P2 2, P3 1 | 2 | 1 |
| Bristol-Myers Squibb BMY | 3 | P2 1, NA 1, P3 1 | 1 | 0 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 2 | NA 1, P3 1 | 0 | 0 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2 | P2 1, P3 1 | 1 | 1 |
| Can-Fite BioPharma CANF | 1 | P3 1 | 0 | 0 |
| Chengdu New Radiomedicine Technology Co. LTD. | 1 | P3 1 | 0 | 0 |
| CStone Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| Guangzhou Virotech Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| InnoBM Pharmaceuticals Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 1 | P3 1 | 0 | 0 |
| Nanjing Sanhome Pharmaceutical, Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Polaris Group PII | 1 | P3 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Tempest Therapeutics TPST | 1 | P3 1 | 0 | 0 |
| Zhejiang Raygene Pharmaceuticals Co., Ltd | 1 | P3 1 | 0 | 0 |
| Boston Scientific Corporation BSX | 3 | NA 2, P2 1 | 1 | 0 |
Recently stopped trials
- NCT05603572 Primocure Pharma - terminated: discontinued enrollment KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
- NCT06487559 AbbVie - terminated: Strategic considerations A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT03812874 TCM Biotech International Corp. - withdrawn: Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study. A Study of PTX-9908 Injection for Non-resectable HCC With TACE
- NCT05359861 Coherus Oncology, Inc. - terminated: Sponsor decision Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
- NCT00423306 Alaunos Therapeutics - terminated: Study closed after Stage 1 (15 of 40 planned patients treated) due to lack of treatment response; criteria to proceed to Stage 2 were not me A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
- NCT05908786 Hoffmann-La Roche - terminated: Study was closed early as the sponsor decided not to continue development of certain treatment combinations. A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resecta
- NCT04246177 Merck Sharp & Dohme LLC - terminated: Business Reasons Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoem
- NCT05435014 T-ACE Medical Co., Ltd - terminated: T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug Administration (FDA) to request the permanent disc T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | Akeso | NCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | HCC; Hepatocellular Carcinoma | not yet recruiting | 120 |
| 2026-11-30 est. | P2 | AstraZeneca AZN | NCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 114 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04344158 A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | 648 |
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P2 | Lion TCR Pte. Ltd. | NCT05195294 Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma | not yet recruiting | 55 |
| 2026-12 est. | P1/P2 | OriCell Therapeutics Co., Ltd. | NCT05652920 Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | Hepatocellular Carcinoma | recruiting | 105 |
| 2026-12 est. | P2 | Zhejiang Haichang Biotech Co., Ltd. | NCT06309485 Phase 2 Study of WGI-0301 for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC) | recruiting | 60 |
| 2026-12-30 est. | P2 | Teclison Ltd. | NCT03259867 Combination of TATE and PD-1 Inhibitor in Liver Cancer | Hepatocellular Carcinoma; Gastric Cancer | recruiting | 54 |
| 2026-12-31 est. | P2 | TaiRx, Inc. | NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma; Advanced Cancer | recruiting | 95 |
| 2027-01 est. | P2/P3 | AbbVie ABBV | NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a | Hepatocellular Carcinoma | active not recruiting | 89 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-02-10 est. | P2 | Shanghai Henlius Biotech | NCT06349980 A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advan | Carcinoma, Hepatocellular | recruiting | 117 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-01 est. | P2/P3 | Mirror Biologics, Inc. | NCT05033522 Immunotherapy for Advanced Liver Cancer | Hepatocellular Carcinoma | suspended | 150 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab | Hepatocellular Carcinoma | active not recruiting | 130 |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | Carcinoma, Hepatocellular | recruiting | 90 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10-14 est. | P3 | Hoffmann-La Roche | NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and B | Unresectable Hepatocellular Carcinoma | active not recruiting | 557 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular | Advanced Hepatocellular Carcinoma | recruiting | 590 |
| 2026-10 est. | P1/P2 | Biotheus Inc. | NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | HCC; Liver Cancer | not yet recruiting | 140 |
| 2026-09-30 est. | P3 | AstraZeneca AZN | NCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC | Hepatocellular Carcinoma | active not recruiting | 214 |
| 2026-09 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 90 |
| 2026-08-14 | P1/P2 | TCM Biotech International Corp. | NCT03812874 A Study of PTX-9908 Injection for Non-resectable HCC With TACE | Carcinoma, Hepatocellular | withdrawn | |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-07-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04639180 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence Afte | Hepatocellular Carcinoma (HCC) | active not recruiting | 687 |
| 2026-07-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05320692 A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 423 |
| 2026-07-09 | P3 | Bristol-Myers Squibb BMY | NCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 732 |
| 2026-06-30 | P2 | AstraZeneca AZN | NCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular | Hepatocellular Carcinoma (HCC) | active not recruiting | 58 |
| 2026-06-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | unknown | 129 |
| 2026-06-15 | P1/P2 | T-ACE Medical Co., Ltd | NCT05435014 T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma | terminated | 2 |
| 2026-06 est. | P1/P2 | Akeso | NCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | recruiting | 280 |
| 2026-05-27 | P3 | Bristol-Myers Squibb BMY | NCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Hepatocellular Carcinoma; Liver Cancer | active not recruiting | 545 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hepatocellular carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.